Advancing schizophrenia drug discovery: Optimizing rodent models to bridge the translational gap

Nature Reviews Drug Discovery

Volumn 11, Issue 7, 2012, Pages 560-570

  Pratt, Judith ^a,b   Winchester, Catherine ^a,b   Dawson, Neil ^a,b   Morris, Brian ^b,c  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; GLUTAMIC ACID; HALOPERIDOL; MODAFINIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NICOTINIC AGENT; OLANZAPINE; PHENCYCLIDINE; PHOSPHODIESTERASE INHIBITOR; QUETIAPINE; RISPERIDONE; SEROTONIN 6 ANTAGONIST; THIORIDAZINE;

AGRANULOCYTOSIS; ANTICHOLINERGIC SYNDROME; BLURRED VISION; COGNITIVE DEFECT; CONSTIPATION; DISEASE MODEL; DOSE RESPONSE; DRUG DETERMINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; GABAERGIC TRANSMISSION; GENETIC ARCHITECTURE; GENETIC MODEL; HEREDITY; HUMAN; INTERMEDIATE PHENOTYPE; MODEL; NARCOLEPSY; NEGATIVE SYNDROME; NERVE CELL NETWORK; NEURODEVELOPMENTAL MODEL; NEUROIMAGING; NONHUMAN; PATHOGENESIS; PHENOTYPE; PHENOTYPIC VARIATION; POSITIVE SYNDROME; PREPULSE INHIBITION; PRIORITY JOURNAL; REVIEW; SALIVATION; SCHIZOPHRENIA; SIDE EFFECT; TRANSGENIC MOUSE; WEIGHT GAIN; XEROSTOMIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; RODENTIA; SCHIZOPHRENIA; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84863208356     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3649     Document Type: Review

References (187)

1. Van Os, J., Kenis, G. & Rutten, B. P. F. The environment and schizophrenia. Nature 468, 203-212 (2010).
2. Insel, T. R. Rethinking schizophrenia. Nature 468, 187-193 (2010).
3. Lieberman, J. A., Miyamoto, S., Duncan, G. E. & Marx, C. E. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10, 79-104 (2005). (Pubitemid 40139590)
4. Laruelle, M. et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl Acad. Sci. USA 93, 9235-9240 (1996).
5. Howes, O. D. et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatry 66, 13-20 (2009).
6. Kapur, S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 160, 13-23 (2003). (Pubitemid 36042420)
7. Lieberman. J. A. & Stroup, T. S. The NIMH-CATIE Schizophrenia Study: what did we learn? Am. J. Psychiatry. 168, 770-775 (2011).
8. Nasrallah, H. A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol. Psychiatry 13, 27-35 (2008). (Pubitemid 350275185)
9. Meltzer, H. Y. What's atypical about atypical antipsychotic drugs? Curr. Opin. Pharmacol. 4, 53-57 (2004). (Pubitemid 38145838)
10. Green, M. F., Kern, R. S. & Heaton, R. K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr. Res. 72, 41-51 (2004). (Pubitemid 39452904)
11. Millan, M. J. et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nature Rev. Drug Discov. 11, 141-168 (2012).
12. Krystal, J. H. et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199-214 (1994). (Pubitemid 24081509)
13. Javitt, D. C. & Zukin, S. R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148, 1301-1308 (1991).
14. Paz, R. D., Tardito, S., Atzori, M. & Tseng, K. Y. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur. Neuropsychopharmacol. 18, 773-786 (2008).
15. Adams, B. W. & Moghaddam, B. Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol. Psychiatry 50, 750-757 (2001). (Pubitemid 33086762)
16. Li, N. et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959-964 (2010).
17. Nudmamud-Thanoi S., Piyabhan P., Harte M. K., Cahir M. & Reynolds G. P. Deficits of neuronal glutamatergic markers in the caudate nucleus in schizophrenia. J. Neural Transm. Suppl. 72, 281-285 (2007).
18. Harrison, P. J., Law, A. J. & Eastwood, S. L. Glutamate receptors and transporters in the hippocampus in schizophrenia. Ann. NY Acad. Sci. 1003, 94-101 (2003). (Pubitemid 38083047)
19. Harrison, P. J. & Eastwood, S. L. Vesicular glutamate transporter (VGLUT) gene expression provides further evidence for glutamatergic synaptic pathology in the hippocampus in schizophrenia. Schizophr. Res. 60, S62-S63 (2003).
20. Kristiansen, L. V., Huerta, I., Beneyto, M. & Meador-Woodruff, J. H. NMDA receptors and schizophrenia. Curr. Opin. Pharmacol. 7, 48-55 (2007).
21. Kirov, G. et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol. Psychiatry 17, 142-153 (2012).
22. Schwartz, T. L., Sachdeva, S. & Stahl, S. M. 'Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia'. Curr. Pharm. Des. 18, 1580-1592 (2012).
23. Large, C. H. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J. Psychopharmacol. 21, 283-301 (2007). (Pubitemid 46934046)
24. Hagan, J. J. & Jones, D. N. C. Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr. Bull. 31, 830-853 (2005). (Pubitemid 41437777)
25. Heekeren, K. et al. Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis. J. Psychopharmacol. 21, 312-320 (2007). (Pubitemid 46934051)
26. Sams-Dodd, F. Effects of dopamine agonists and antagonists on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Psychopharmacology 135, 182-193 (1998). (Pubitemid 28055502)
27. Young, J. W., Powell, S. B., Risbrough, V., Marston, H. M. & Geyer, M. A. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol. Ther. 122, 150-202 (2009).
28. Thomson, D. M., Mcvie, A., Morris, B. J. & Pratt, J. A. Dissociation of acute and chronic intermittent phencyclidine-induced performance deficits in the 5-choice serial reaction time task: influence of clozapine. Psychopharmacology 213, 681-695 (2011).
29. Amitai, N. & Semenova, S. & Markou, A. Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. Psychopharmacology 193, 521-537 (2007). (Pubitemid 47094377)
30. Thomsen, M. S., Hansen, H. H., Timmerman, D. B. & Mikkelsen, J. D. Cognitive improvement by activation of α7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr. Pharm. Des. 16, 323-343 (2010).
31. Martin, L. F., Kem, W. R. & Freedman, R. α-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology 174, 54-64 (2004). (Pubitemid 38925091)
32. Freedman, R. et al. Initial Phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry 165, 1040-1047 (2008).
33. Morein-Zamir, S., Turner, D. C. & Sahakian, B. J. A review of the effects of modafinil on cognition in schizophrenia. Schizophr. Bull. 33, 1298-1306 (2007). (Pubitemid 350022777)
34. Scoriels, L., Barnett, J. H., Soma, P. K., Sahakian, B. J. & Jones, P. B. Effects of modafinil on cognitive functions in first episode psychosis. Psychopharmacology 220, 249-258 (2012).
35. Goetghebeur, P. & Dias, R. Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat-a back translational study. Psychopharmacology 202, 287-293 (2009).
36. Pratt, J. A., Dawson, N., Winchester, C. L., Thomson, D. M. & Morris, B. J. Distinct aspects of prefrontal cortex dysfunction in schizophrenia modelled by acute and repeated PCP treatment: impact of modafinil. Schizophr. Res. 117, 509 (2010).
37. Rodefer, J. S., Murphy, E. R. & Baxter, M. G. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur. J. Neurosci. 21, 1070-1076 (2005). (Pubitemid 40461058)
38. Hatcher, P. D. et al. 5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats. Psychopharmacology 181, 253-259 (2005). (Pubitemid 41492195)
39. Morris, B. J., Cochran, S. M. & Pratt, J. A. PCP: from pharmacology to modelling schizophrenia. Curr. Opin. Pharmacol. 5, 101-106 (2005). (Pubitemid 40124542)
40. Gonzalez-Burgos, G. & Lewis, D. A. NMDA receptor hypofunction, parvalbumin-positive neurons and cortical γ oscillations in schizophrenia. Schizophr. Bull. 21 Feb 2012 (doi:10.1093/schbul/sbs010).
41. Lewis, D. A., Hashimoto, T. & Volk, D. W. Cortical inhibitory neurons and schizophrenia. Nature Rev. Neurosci. 6, 312-324 (2005). (Pubitemid 40469985)
42. Benes, F. M. & Berretta, S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25, 1-27 (2001). (Pubitemid 32493819)
43. Ellenbroek, B. A. & Cools, A. R. The neurodevelopment hypothesis of schizophrenia: clinical evidence and animal models. Neurosci. Res. Commun. 22, 127-136 (1998). (Pubitemid 28305949)
44. Hayashi-Takagi, A. & Sawa, A. Disturbed synaptic connectivity in schizophrenia: convergence of genetic risk factors during neurodevelopment. Brain Res. Bull. 83, 140-146 (2010).
45. Charych, E. I., Liu, F., Moss, S. J. & Brandon, N. J. GABAA receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders. Neuropharmacology 57, 481-495 (2009).
46. Kim, J. Y. et al. Interplay between DISC1 and GABA signaling regulates neurogenesis in mice and risk for schizophrenia. Cell 148, 1051-1064 (2012).
47. Atack, J. R. GABAA receptor α2/α3 subtype-selective modulators as potential nonsedating anxiolytics. Curr. Top. Behav. Neurosci. 2, 331-360 (2011).
48. Brown, A. S. The environment and susceptibility to schizophrenia. Prog. Neurobiol. 93, 23-58 (2011).
49. Tseng, K. Y., Chambers, R. A. & Lipska, B. K. The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav. Brain Res. 204, 295-305 (2009).
50. SamsDodd, F., Lipska, B. K. & Weinberger, D. R. Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology 132, 303-310 (1997). (Pubitemid 27351432)
51. Becker, A., Grecksch, G., Bernstein, H. G., Hollt, V. & Bogerts, B. Social behaviour in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis. Psychopharmacology 144, 333-338 (1999). (Pubitemid 29307257)
52. Le Pen, G. et al. Impact of chronic antipsychotic treatments on hypersensitivity to MK-801 in a neurodevelopmental model of schizophrenia. Eur. Neuropsychopharmacol. 17, S480-S481 (2007).
53. Lodge, D. J. & Grace, A. A. Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav. Brain Res. 204, 306-312 (2009).
54. Fone, K. C. F. & Porkess, M. V. Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders. Neurosci. Biobehav. Rev. 32, 1087-1102 (2008).
55. Bitanihirwe, B. K. Y., Peleg-Raibstein, D., Mouttet, F., Feldon, J. & Meyer, U. Late prenatal immune activation in mice leads to behavioral abnormalities relevant to the negative symptoms of schizophrenia. Schizophr. Res. 117, 273-274 (2010).
56. Ozawa, K. et al. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol. Psychiatry 59, 546-554 (2006). (Pubitemid 43320543)
57. Cardno, A. G., Rijsdijk, F. V., Gottesman, I. I. & McGuffin, P. Heritability estimates for psychotic symptom dimensions in twins with psychotic disorders. Am. J. Med. Genet. B Neuropsychiatr. Genet. 156B, 89-98 (2011).
58. Mitchell, K. J. What is complex about complex disorders? Genome Biol. 13, 237 (2012).
59. Purcell, S. M. et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460, 748-752 (2009).
60. Ayhan, Y., Sawa, A., Ross, C. A. & Pletnikov, M. V. Animal models of gene-environment interactions in schizophrenia. Behav. Brain Res. 204, 274-281 (2009).
61. Arguello, P. A. & Gogos, J. A. Genetic and cognitive windows into circuit mechanisms of psychiatric disease. Trends Neurosci. 35, 3-13 (2012).
62. Allen, N. C. et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nature Genet. 40, 827-834 (2008). (Pubitemid 351913655)
63. Swerdlow, N. R., Geyer, M. A. & Braff, D. L. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology 156, 194-215 (2001). (Pubitemid 32702213)
64. van den Buuse, M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr. Bull. 36, 246-270 (2010).
65. Kellendonk, C. et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 49, 603-615 (2006). (Pubitemid 43221894)
66. Fitzgerald, P. J. et al. Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder? Neurobiol. Dis. 40, 608-621 (2010).
67. Bannerman, D. M. et al. NMDA receptor subunit NR2A is required for rapidly acquired spatial working memory but not incremental spatial reference memory. J. Neurosci. 28, 3623-3630 (2008).
68. Inta, D., Monyer, H., Sprengel, R., Meyer-Lindenberg, A. & Gass, P. Mice with genetically altered glutamate receptors as models of schizophrenia: a comprehensive review. Neurosci. Biobehav. Rev. 34, 285-294 (2010).
69. Clapcote, S. J. et al. Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 54, 387-402 (2007). (Pubitemid 46671409)
70. Lipina, T. V. et al. Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3. Synapse 65, 234-248 (2011).
71. Boulay, D. et al. Comparative phenotype in behavioral models related to schizophrenia: Disc1 (L100P) mutant, NMDA Nr1neo-/-hypomorphic and DAT-/-mice. Program No. 766.1 2010 Neuroscience Meeting Planner (San Diego, California; Society for Neuroscience, 2010).
72. Shoji, H. et al. Comprehensive behavioral analysis of ENU-induced Disc1-Q131L and-L100P mutant mice. BMC Res. Notes 5, 108 (2012).
73. Shen, S. et al. Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated Disc1. J. Neurosci. 28, 10893-10904 (2008).
74. Kvajo, M. et al. Altered axonal targeting and short-term plasticity in the hippocampus of Disc1 mutant mice. Proc. Natl Acad. Sci. USA 108, E1349-E1358 (2011).
75. Gainetdinov, R. R. Dopamine transporter mutant mice in experimental neuropharmacology. Naunyn Schmiedebergs Arch. Pharmacol. 377, 301-313 (2008).
76. Powell, S. B., Young, J. W., Ong, J. C., Caron, M. G. & Geyer, M. A. Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice. Behav. Pharmacol. 19, 562-565 (2008).
77. Wen, L. et al. Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons. Proc. Natl Acad. Sci. USA 107, 1211-1216 (2010).
78. Simpson, E. H. et al. Pharmacologic rescue of motivational deficit in an animal model of the negative symptoms of schizophrenia. Biol. Psychiatry 69, 928-935 (2011).
79. Pearlson, G. D. & Calhoun, V. D. Convergent approaches for defining functional imaging endophenotypes in schizophrenia. Front. Hum. Neurosci. 3, 37 (2009).
80. Braff, D. L., Freedman, R., Schork, N. J. & Gottesman, I. I. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr. Bull. 33, 21-32 (2007). (Pubitemid 46026257)
81. Callicott, J. H. et al. Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. Am. J. Psychiatry 160, 2209-2215 (2003). (Pubitemid 39619615)
82. Potkin, S. G. et al. Working memory and DLPFC inefficiency in schizophrenia: the FBIRN study. Schizophr. Bull. 35, 19-31 (2009).
83. McIntosh, A. R., Nyberg, L., Bookstein, F. L. & Tulving, E. Differential functional connectivity of prefrontal and medial temporal cortices during episodic memory retrieval. Hum. Brain Mapp. 5, 323-327 (1997). (Pubitemid 27375535)
84. Friston, K. J. & Frith, C. D. Schizophrenia: a disconnection syndrome. Clin. Neurosci. 3, 89-97 (1995).
85. Meyer-Lindenberg, A. et al. Evidence for abnormal cortical functional connectivity during working memory in schizophrenia. Am. J. Psychiatry 158, 1809-1817 (2001). (Pubitemid 33054773)
86. Mcintosh, A. R. & Gonzalezlima, F. Structural modeling of functional neural pathways mapped with 2-deoxyglucose: effects of acoustic startle habituation on the auditory-system. Brain Res. 547, 295-302 (1991).
87. Dawson, N. et al. Modafinil reverses phencyclidine-induced deficits in cognitive flexibility, cerebral metabolism, and functional brain connectivity. Schizophr. Bull. 38, 457-474 (2012).
88. Cochran, S. M. et al. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28, 265-275 (2003).
89. Hunter, M., Ganesan, V. S. & Spence, S. A. Effects of modafinil on prefrontal function and voluntary behaviour in chronic schizophrenia. Schizophr. Bull. 31, 511-512 (2005).
90. Spence, S. A., Green, R. D., Wilkinson, I. D. & Hunter, M. D. Modafinil modulates anterior cingulate function in chronic schizophrenia. Br. J. Psychiatry 187, 55-61 (2005). (Pubitemid 41002514)
91. Minzenberg, M. J. et al. Response to comment on "modafinil shifts human locus coeruleus to low-tonic, high-phasic activity during functional MRI". Science 328, 309 (2010).
92. Pratt, J. A., Winchester, C., Egerton, A., Cochran, S. M. & Morris, B. J. Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. Br. J. Pharmacol. 153, S465-S470 (2008). (Pubitemid 351341020)
93. Egerton, A. et al. Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats. Psychopharmacology 198, 37-49 (2008).
94. Bullmore, E. & Sporns, O. Complex brain networks: graph theoretical analysis of structural and functional systems. Nature Rev. Neurosci. 10, 186-198 (2009).
95. Bullmore, E. et al. Hierarchical organization of human cortical networks in health and schizophrenia. J. Neurosci. 28, 9239-9248 (2008).
96. Micheloyannis, S. et al. Small-world networks and disturbed functional connectivity in schizophrenia. Schizophr. Res. 87, 60-66 (2006). (Pubitemid 44428137)
97. Liu, Y. et al. Disrupted small-world networks in schizophrenia. Brain 131, 945-961 (2008). (Pubitemid 351499423)
98. Dawson, N., Higham, D., Pratt, J. & Morris, B. Alterations in functional brain network structure induced by subchronic phencyclidine (PCP) treatment parallel those seen in schizophrenia. Schizophr. Res. 117, 234-235 (2010).
99. Fuchs, E. C. et al. Recruitment of parvalbumin-positive interneurons determines hippocampal function and associated behavior. Neuron 53, 591-604 (2007). (Pubitemid 46216760)
100. Sohal, V. S. Insights into cortical oscillations arising from optogenetic studies. Biol. Psychiatry 71, 1039-1045 (2012).
101. Wulff, P. et al. Hippocampal theta rhythm and its coupling with gamma oscillations require fast inhibition onto parvalbumin-positive interneurons. Proc. Natl Acad. Sci. USA 106, 3561-3566 (2009).
102. Haenschel, C. et al. Cortical oscillatory activity is critical for working memory as revealed by deficits in early-onset schizophrenia. J. Neurosci. 29, 9481-9489 (2009).
103. Uhlhaas, P. J. et al. Impaired γ-band synchrony during dysfunctional gestalt perception in schizophrenia. Biol. Psychiatry 59, 5S (2006).
104. Jaaro-Peled, H., Ayhan, Y., Pletnikov, M. V. & Sawa, A. Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models. Schizophr. Bull. 36, 301-313 (2010).
105. Sigurdsson, T., Stark, K. L., Karayiorgou, M., Gogos, J. A. & Gordon, J. A. Impaired hippocampal-prefrontal synchrony in a genetic mouse model of schizophrenia. Nature 464, 763-767 (2010).
106. Lawrie, S. M., Hall, J., McIntosh, A. M., Cunningham-Owens, D. G. & Johnstone, E. C. Neuroimaging and molecular genetics of schizophrenia: pathophysiological advances and therapeutic potential. Br. J. Pharmacol. 153, S120-S124 (2008). (Pubitemid 351341009)
107. Weinberger, D. et al. Plenary session-on the matter of neuroimaging in the context of schizophrenia genetics. Schizophr. Res. 117, 109-110 (2010).
108. Egan, M. F. et al. Effect of COMT Val(108/158) Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl Acad. Sci. USA 98, 6917-6922 (2001). (Pubitemid 32538317)
109. Egan, M. F. et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc. Natl Acad. Sci. USA 101, 12604-12609 (2004). (Pubitemid 39122071)
110. Weinberger, D. R. et al. A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nature Med. 15, 509-518 (2009).
111. Callicott, J. et al. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Neuropsychopharmacology 101, 12604-12609 (2004). (Pubitemid 39122071)
112. Straub, R. E. et al. Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. Mol. Psychiatry 12, 854-869 (2007). (Pubitemid 47347790)
113. McIntosh, A. M. et al. The effects of a neuregulin 1 variant on white matter density and integrity. Mol. Psychiatry 13, 1054-1059 (2008).
114. Esslinger, C. et al. Cognitive state and connectivity effects of the genome-wide significant psychosis variant in ZNF804A. Neuroimage 54, 2514-2523 (2011).
115. Potkin, S. G. et al. Gene discovery through imaging genetics: identification of two novel genes associated with schizophrenia. Mol. Psychiatry 14, 416-428 (2009).
116. Potkin, S. G. et al. A genome-wide association study of schizophrenia using brain activation as a quantitative phenotype. Schizophr. Bull. 35, 96-108 (2009).
117. Weinberger, D. R. et al. No effect of a common allelic variant in the reelin gene on intermediate phenotype measures of brain structure, brain function, and gene expression. Biol. Psychiatry 68, 105-107 (2010).
118. Bramon, E. et al. Psychosis biological markers and their genetic influences. Schizophr. Res. 117, 217 (2010).
119. Foussias, G. & Remington, G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr. Bull. 36, 359-369 (2010).
120. Heinrichs, R. W. & Zakzanis, K. K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12, 426-445 (1998). (Pubitemid 28323862)
121. Seeman, P. Dopamine D2 receptors as treatment targets in schizophrenia. Clin. Schizophr. Relat. Psychoses 4, 56-73 (2010).
122. Nord, M. & Farde, L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci. Ther. 17, 97-103 (2011).
123. Miyamoto, S., Duncan, G. E., Marx, C. E. & Lieberman, J. A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10, 79-104 (2005). (Pubitemid 40139590)
124. Meltzer, H. Y. & Massey, B. W. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr. Opin. Pharmacol. 11, 59-67 (2011).
125. Meltzer, H. Y. Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review. Br. J. Psychiatry 168, 23-31 (1996). (Pubitemid 26181864)
126. Geyer, M. A., Krebs-Thomson, K., Braff, D. L. & Swerdlow, N. R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156, 117-154 (2001). (Pubitemid 32702206)
127. O'Tuathaigh, C. M. P., Kirby, B. P., Moran, P. M. & Waddington, J. L. Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia. Schizophr. Bull. 36, 271-288 (2010).
128. Wise, R. A. Forebrain substrates of reward and motivation. J. Comp. Neurol. 493, 115-121 (2005). (Pubitemid 41636193)
129. Nuechterlein, K. H., Luck, S. J., Lustig, C. & Sarter, M. CNTRICS final task selection: control of attention. Schizophr. Bull. 35, 182-196 (2009).
130. Bari, A., Dalley, J. W. & Robbins, T. W. The application of the 5-choice serial reaction time task for the assessment of visual attentional processes and impulse control in rats. Nature Protoc. 3, 759-767 (2008). (Pubitemid 351639020)
131. Joyce, E. et al. Executive dysfunction in first-episode schizophrenia and relationship to duration of untreated psychosis: the West London Study. Br. J. Psychiatry 181, S38-S44 (2002). (Pubitemid 34983511)
132. Birrell, J. M. & Brown, V. J. Medial frontal cortex mediates perceptual attentional set shifting in the rat. J. Neurosci. 20, 4320-4324 (2000). (Pubitemid 30365702)
133. Arguello, P. A. & Gogos, J. A. Cognition in mouse models of schizophrenia susceptibility genes. Schizophr. Bull. 36, 289-300 (2010).
134. Marighetto, A. et al. Comparative effects of the dopaminergic agonists piribedil and bromocriptine in three different memory paradigms in rodents. J. Psychopharmacol. 22, 511-521 (2008).
135. Crawley, J. N. et al. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology 132, 107-124 (1997). (Pubitemid 27338986)
136. Brandon, N. J. et al. Understanding the role of DISC1 in psychiatric disease and during normal development. J. Neurosci. 29, 12768-12775 (2009).
137. Koike, H., Arguello, P. A., Kvajo, M., Karayiorgou, M. & Gogos, J. A. Disc1 is mutated in the 129S6/SvEv strain and modulates working memory in mice. Proc. Natl Acad. Sci. USA 103, 3693-3697 (2006). (Pubitemid 43376617)
138. Kvajo, M. et al. A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc. Natl Acad. Sci. USA 105, 7076-7081 (2008). (Pubitemid 351754532)
139. Hikida, T. et al. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc. Natl Acad. Sci. USA 104, 14501-14506 (2007). (Pubitemid 350003290)
140. Niwa, M. et al. Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits. Neuron 65, 480-489 (2010).
141. Abazyan, B. et al. Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. Biol. Psychiatry 68, 1172-1181 (2011).
142. Pletnikov, M. V. et al. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol. Psychiatry 13, 173-186 (2008).
143. Li, W. et al. Specific developmental disruption of disrupted-in- schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc. Natl Acad. Sci. USA 104, 18280-18285 (2007). (Pubitemid 350210858)
144. Kuroda, K. et al. Behavioral alterations associated with targeted disruption of exons 2 and 3 of the Disc1 gene in the mouse. Hum. Mol. Genet. 20, 4666-4683 (2011).
145. Stefansson, H. et al. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71, 877-892 (2002). (Pubitemid 135750519)
146. Chen, Y. J. J. et al. Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J. Neurosci. 28, 6872-6883 (2008).
147. O'Tuathaigh, C. M. P. et al. Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1. Neuroscience 147, 18-27 (2007). (Pubitemid 46873845)
148. Golub, M. S., Germann, S. L. & Lloyd, K. C. K. Behavioral characteristics of a nervous system-specific erbB4 knock-out mouse. Behav. Brain Res. 153, 159-170 (2004). (Pubitemid 38829299)
149. Barros, C. S. et al. Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system. Proc. Natl Acad. Sci. USA 106, 4507-4512 (2009).
150. Siuciak, J. A., McCarthy, S. A., Chapin, D. S. & Martin, A. N. Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology 197, 115-126 (2008).
151. Paylor, R. et al. Impaired learning and motor behavior in heterozygous Pafah1b1 (Lis1) mutant mice. Learn. Mem. 6, 521-537 (1999). (Pubitemid 29503848)
152. Long, J. M. et al. Behavior of mice with mutations in the conserved region deleted in velocardiofacial/DiGeorge syndrome. Neurogenetics 7, 247-257 (2006). (Pubitemid 44584078)
153. Paylor, R. et al. Mice deleted for the DiGeorge/velocardiofacial syndrome region show abnormal sensorimotor gating and learning and memory impairments. Hum. Mol. Genet. 10, 2645-2650 (2001). (Pubitemid 33133405)
154. Drago, J. et al. Altered striatal function in a mutant mouse lacking D1A dopamine receptors. Proc. Natl Acad. Sci. USA 91, 12564-12568 (1994).
155. Xu, M. et al. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell 79, 729-742 (1994). (Pubitemid 24363815)
156. Ralph-Williams, R. J., Lehmann-Masten, V., Otero-Corchon, V., Low, M. J. & Geyer, M. A. Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J. Neurosci. 22, 9604-9611 (2002). (Pubitemid 35356202)
157. Clifford, J. J. et al. Topographical evaluation of behavioural phenotype in a line of mice with targeted gene deletion of the D-2 dopamine receptor. Neuropharmacology 39, 382-390 (2000). (Pubitemid 30052927)
158. Kellendonk, C., Simpson, E. H. & Kandel, E. R. Modeling cognitive endophenotypes of schizophrenia in mice. Trends Neurosci. 32, 347-358 (2009).
159. Gogos, J. A. et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc. Natl Acad. Sci. USA 95, 9991-9996 (1998). (Pubitemid 28415282)
160. Babovic, D. et al. Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase. Neuroscience 155, 1021-1029 (2008).
161. Giros, B., Morice, E., Denis, C. & Nosten-Bertrand, M. Phenotypic expression of the targeted null-mutation in the dopamine transporter gene varies as a function of the genetic background. Eur. J. Neurosci. 20, 120-126 (2004). (Pubitemid 38932133)
162. Morice, E. et al. Parallel loss of hippocampal LTD and cognitive flexibility in a genetic model of hyperdopaminergia. Neuropsychopharmacology 32, 2108-2116 (2007). (Pubitemid 47417702)
163. Mohn, A. R., Gainetdinov, R. R., Caron, M. G. & Koller, B. H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98, 427-436 (1999). (Pubitemid 29402481)
164. Duncan, G. E. et al. Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav. Brain Res. 153, 507-519 (2004). (Pubitemid 38953128)
165. Miyamoto, Y. et al. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor ε1 subunit. J. Neurosci. 21, 750-757 (2001). (Pubitemid 32107463)
166. Boyce-Rustay, J. M. & Holmes, A. Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic-and antidepressant-like effects in mice. Neuropsychopharmacology 31, 2405-2414 (2006). (Pubitemid 44607058)
167. Schmitt, W. B., Deacon, R. M. J., Seeburg, P. H., Rawlins, J. N. P. & Bannerman, D. M. A within-subjects, within-task demonstration of intact spatial reference memory and impaired spatial working memory in glutamate receptor-A-deficient mice. J. Neurosci. 23, 3953-3958 (2003). (Pubitemid 36958501)
168. Barkus, C. et al. Do GluA1 knockout mice exhibit behavioral abnormalities relevant to the negative or cognitive symptoms of schizophrenia and schizoaffective disorder? Neuropharmacology 62, 1263-1272 (2011).
169. Wiedholz, L. M. et al. Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and 'schizophrenia-related' behaviors. Mol. Psychiatry 13, 631-640 (2008). (Pubitemid 351704934)
170. Sagata, N. et al. Comprehensive behavioural study of GluR4 knockout mice: implication in cognitive function. Genes Brain Behav. 9, 899-909 (2010).
171. Belforte, J. E. et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nature Neurosci. 13, 76-83 (2010).
172. Tordera, R. M. et al. Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1). Eur. J. Neurosci. 25, 281-290 (2007). (Pubitemid 46096241)
173. Garcia-Garcia, A. L. et al. Increased vulnerability to depressive-like behavior of mice with decreased expression of VGLUT1. Biol. Psychiatry 66, 275-282 (2009).
174. Chen, Y. W. & Lai, W. S. Behavioral phenotyping of V-Akt murine thymoma viral oncogene homolog 1-deficient mice reveals a sex-specific prepulse inhibition deficit in females that can be partially alleviated by glycogen synthase kinase-3 inhibitors but not by antipsychotics. Neuroscience 174, 178-189 (2011).
175. Lai, W. S. et al. Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc. Natl Acad. Sci. USA 103, 16906-16911 (2006).
176. Cox, M. M. et al. Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/56J genetic background. Genes Brain Behav. 8, 390-397 (2009).
177. Jentsch, J. D. et al. Dysbindin modulates prefrontal cortical glutamatergic circuits and working memory function in mice. Neuropsychopharmacology 34, 2601-2608 (2009).
178. Carlson, G. C. et al. Dysbindin-1 mutant mice implicate reduced fast-phasic inhibition as a final common disease mechanism in schizophrenia. Proc. Natl Acad. Sci. USA 108, E962-E970 (2011).
179. Papaleo, F. et al. Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways. Mol. Psychiatry 17, 85-98 (2012).
180. Korotkova, T., Fuchs, E. C., Ponomarenko, A., von Engelhardt, J. & Monyer, H. NMDA receptor ablation on parvalbumin-positive interneurons impairs hippocampal synchrony, spatial representations, and working memory. Neuron 68, 557-569 (2010).
181. Lipina, T. V. et al. Enhanced dopamine function in DISC1-L100P mutant mice: implications for schizophrenia. Genes Brain Behav. 9, 777-789 (2010).
182. Hiroi, N. et al. A 200-kb region of human chromosome 22q11.2 confers antipsychotic-responsive behavioral abnormalities in mice. Proc. Natl Acad. Sci. USA 102, 19132-19137 (2005). (Pubitemid 43049578)
183. Duncan, G. E., Moy, S. S., Lieberman, J. A. & Koller, B. H. Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction. Pharmacol. Biochem. Behav. 85, 481-491 (2006). (Pubitemid 46097058)
184. Duncan, G. E., Moy, S. S., Lieberman, J. A. & Koller, B. H. Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function. Psychopharmacology 184, 190-200 (2006). (Pubitemid 43083656)
185. Fradley, R. L. et al. STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav. Brain Res. 163, 257-264 (2005). (Pubitemid 41138060)
186. Brody, S. A., Conquet, F. & Geyer, M. A. Disruption of prepulse inhibition in mice lacking mGluR1. Eur. J. Neurosci. 18, 3361-3366 (2003). (Pubitemid 38031061)
187. Brody, S. A., Conquet, F. & Geyer, M. A. Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice. Psychopharmacology 172, 187-195 (2004). (Pubitemid 38388768)